PathMaker Reports Non-Invasive Stimulation Cut Toxic TDP-43 Aggregates 76% in ALS Mouse Model

Summary

PathMaker Neurosystems, a clinical-stage ALS neurotechnology company, announced a peer-reviewed paper in Neuromodulation, the journal of the International Neuromodulation Society, reporting that its non-invasive Multi-Site DCS technology, which delivers direct current at several sites along the body, reduced toxic TDP-43 protein aggregates in spinal motor neurons in a mouse model of ALS. After four weeks of stimulation three times a week, TDP-43 particles per motor neuron fell 76% against unstimulated mice, alongside better motor function, preserved motor neuron size, and higher levels of the chaperone protein HSP70; in a second model, SOD1-G93A, stimulated mice again kept stronger motor performance. The senior author is Zaghloul Ahmed of CUNY College of Staten Island, PathMaker's scientific founder. The work is preclinical and the figures come from the company's announcement. Its MyoRegulator device is investigational, holds FDA Breakthrough Device Designation for ALS, and is being tested in the DoD-funded CALM trial, with a second ALS trial nearing full enrollment, the company says.